Schering AG U.S. Expansion Plans Call For Sales Of $1.6 Bil. In 2005
Executive Summary
Schering AG expects its U.S. business to approach $1.6 bil. in revenues by 2005, more than double its projected 1999 level of $750 mil.
You may also be interested in...
Immunex Novantrone MS Use Is Likely To Be Second-Line
Immunex expects Novantrone (mitoxantrone) would be used primarily as second-line therapy if approved for the treatment of multiple sclerosis.
Immunex Novantrone MS Use Is Likely To Be Second-Line
Immunex expects Novantrone (mitoxantrone) would be used primarily as second-line therapy if approved for the treatment of multiple sclerosis.
Teva Acquisition Spree Gives Firm A Boost With Analysts
Anticipation of another merger is helping Teva improve its standing with Wall Street analysts.